Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 435

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Open access
Guimarães, Patrícia O., Quirk, Daniel, Furtado, Remo H., Maia, Lilia N., Saraiva, José F., Antunes, Murillo O., Kalil Filho, Roberto, Junior, Vagner M., Soeiro, Alexandre M., Tognon, Alexandre P., Veiga, Viviane C., Martins, Priscilla A., Moia, Diogo D.F., Sampaio, Bruna S., Assis, Silvia R.L., Soares, Ronaldo V.P., Piano, Luciana P.A., Castilho, Kleber, Momesso, Roberta G.R.A.P., Monfardini, Frederico, Guimarães, Helio P., Ponce de Leon, Dario, Dulcine, Majori, Pinheiro, Marcia R.T., Gunay, Levent M., Deuring, J. Jasper, Rizzo, Luiz V., Koncz, Tamas, Berwanger, Otavio·2021·New England Journal of Medicine
DOI 10.1056/nejmoa2101643
Open this paper in CoChat — free account

Abstract

BACKGROUND: The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear. METHODS: We randomly assigned, in a 1:1 ratio, hospitalized adults with Covid-19 pneumonia to receive either tofacitinib at a dose of 10 mg or placebo twice daily for up to 14 days or until hospital discharge. The primary outcome was the occurrence of death or respiratory failure through day 28 as assessed with the use of an eight-level ordinal scale (with scores ranging from 1 to 8 and higher scores indicating a worse condition). All-cause mortality and safety were also assessed. RESULTS: A total of 289 patients underwent randomization at 15 sites in Brazil. Overall, 89.3% of the patients received glucocorticoids during hospitalization. The cumulative incidence of death or respiratory failure through day 28 was 18.1% in the tofacitinib group and 29.0% in the placebo group (risk ratio, 0.63; 95% confidence interval [CI], 0.41 to 0.97; P = 0.04). Death from any cause through day 28 occurred in 2.8% of the patients in the tofacitinib group and in 5.5% of those in the placebo group (hazard ratio, 0.49; 95% CI, 0.15 to 1.63). The proportional odds of having a worse score on the eight-level ordinal scale with tofacitinib, as compared with placebo, was 0.60 (95% CI, 0.36 to 1.00) at day 14 and 0.54 (95% CI, 0.27 to 1.06) at day 28. Serious adverse events occurred in 20 patients (14.1%) in the tofacitinib group and in 17 (12.0%) in the placebo group. CONCLUSIONS: Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. (Funded by Pfizer; STOP-COVID ClinicalTrials.gov number, NCT04469114.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2101643

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 435

Metadata

Authors
Guimarães, P. O., Quirk, D., Furtado, R. H., Maia, L. N., Saraiva, J. F., Antunes, M. O., Kalil Filho, R., Junior, V. M., Soeiro, A. M., Tognon, A. P., Veiga, V. C., Martins, P. A., Moia, D. D. F., Sampaio, B. S., Assis, S. R. L., Soares, R. V. P., Piano, L. P. A., Castilho, K., Momesso, R. G. R. A. P., Monfardini, F., Guimarães, H. P., Ponce de Leon, D., Dulcine, M., Pinheiro, M. R. T., Gunay, L. M., Deuring, J. J., Rizzo, L. V., Koncz, T., & Berwanger, O.
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2021-07-29
Volume
385
Issue
5
Pages
406-415
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa2101643
OpenAlex
W3167671574
Cited by
435
References
29
FWCI
30.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. https://app.cochat.ai/papers/10.1056/nejmoa2101643
The paper
Guimarães, P. O., Quirk, D., Furtado, R. H., Maia, L. N., Saraiva, J. F., Antunes, M. O., Kalil Filho, R., Junior, V. M., Soeiro, A. M., Tognon, A. P., Veiga, V. C., Martins, P. A., Moia, D. D. F., Sampaio, B. S., Assis, S. R. L., Soares, R. V. P., Piano, L. P. A., Castilho, K., Momesso, R. G. R. A. P., . . . Berwanger, O. (2021). Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2101643

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.